Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Lodise

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
American Health & Drug Benefits|August 21, 2019
Cost-Saving Opportunities with an Oral and Intravenous Once-Daily Aminomethylcycline Antibiotic for Hospitalized Patients with Community-Acquired Bacterial Pneumonia: Findings from Decision-Analytic ModelsThomas Lodise, Kenneth LaPensee
American Health & Drug Benefits|February 13, 2019
Potential Cost-Savings with Once-Daily Aminomethylcycline Antibiotic versus Vancomycin in Hospitalized Patients with Acute Bacterial Skin and Skin Structure InfectionsKen LaPensee, Thomas Lodise
Plos One|January 4, 2023
Methods to appraise available evidence and adequacy of data from a systematic literature review to conduct a robust network meta-analysis of treatment options for patients with hospital-acquired or ventilator-associated bacterial pneumoniaLaura Puzniak, Ryan Dillon, Thomas Lodise
Clinical Drug Investigation|August 15, 2018
Potential for Cost Saving with Iclaprim Owing to Avoidance of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure InfectionsNimish Patel, David Huang, Thomas Lodise
American Health & Drug Benefits|April 19, 2019
Budget Impact Model of Omadacycline on Replacing a Proportion of Existing Treatment Options Among Patients Who Present to the Emergency Department with Acute Bacterial Skin and Skin Structure InfectionsKenneth LaPensee, Rohit Mistry, Thomas Lodise
American Health & Drug Benefits|April 19, 2019
Budget Impact of Omadacycline for the Treatment of Patients with Community-Acquired Bacterial Pneumonia in the United States from the Hospital PerspectiveKenneth LaPensee, Rohit Mistry, Thomas Lodise
Antimicrobial Agents and Chemotherapy|June 1, 2017
Prevalence of Invasive Infections Due to Carbapenem-Resistant Enterobacteriaceae among Adult Patients in U.S. HospitalsThomas Lodise, Michael J Ye, Qi Zhao
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 9, 2022
Panacea or oversimplification: Relating AUC and troughsNicholas Rebold, Thomas Lodise, Michael J Rybak
Open Forum Infectious Diseases|July 27, 2018
Association Between Carbapenem Resistance and Mortality Among Adult, Hospitalized Patients With Serious Infections Due to <i>Enterobacteriaceae</i>: Results of a Systematic Literature Review and Meta-analysisAmber Martin, Kyle Fahrbach, Qi Zhao, et al.
Open Forum Infectious Diseases|October 24, 2018
Safety of Delafloxacin: Focus on Adverse Events of Special InterestThomas Lodise, Ralph Corey, David Hooper, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
American Health & Drug Benefits|August 21, 2019
Cost-Saving Opportunities with an Oral and Intravenous Once-Daily Aminomethylcycline Antibiotic for Hospitalized Patients with Community-Acquired Bacterial Pneumonia: Findings from Decision-Analytic ModelsThomas Lodise, Kenneth LaPensee
American Health & Drug Benefits|February 13, 2019
Potential Cost-Savings with Once-Daily Aminomethylcycline Antibiotic versus Vancomycin in Hospitalized Patients with Acute Bacterial Skin and Skin Structure InfectionsKen LaPensee, Thomas Lodise
Plos One|January 4, 2023
Methods to appraise available evidence and adequacy of data from a systematic literature review to conduct a robust network meta-analysis of treatment options for patients with hospital-acquired or ventilator-associated bacterial pneumoniaLaura Puzniak, Ryan Dillon, Thomas Lodise
Clinical Drug Investigation|August 15, 2018
Potential for Cost Saving with Iclaprim Owing to Avoidance of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure InfectionsNimish Patel, David Huang, Thomas Lodise
American Health & Drug Benefits|April 19, 2019
Budget Impact Model of Omadacycline on Replacing a Proportion of Existing Treatment Options Among Patients Who Present to the Emergency Department with Acute Bacterial Skin and Skin Structure InfectionsKenneth LaPensee, Rohit Mistry, Thomas Lodise
American Health & Drug Benefits|April 19, 2019
Budget Impact of Omadacycline for the Treatment of Patients with Community-Acquired Bacterial Pneumonia in the United States from the Hospital PerspectiveKenneth LaPensee, Rohit Mistry, Thomas Lodise
Antimicrobial Agents and Chemotherapy|June 1, 2017
Prevalence of Invasive Infections Due to Carbapenem-Resistant Enterobacteriaceae among Adult Patients in U.S. HospitalsThomas Lodise, Michael J Ye, Qi Zhao
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 9, 2022
Panacea or oversimplification: Relating AUC and troughsNicholas Rebold, Thomas Lodise, Michael J Rybak
Open Forum Infectious Diseases|July 27, 2018
Association Between Carbapenem Resistance and Mortality Among Adult, Hospitalized Patients With Serious Infections Due to <i>Enterobacteriaceae</i>: Results of a Systematic Literature Review and Meta-analysisAmber Martin, Kyle Fahrbach, Qi Zhao, et al.
Open Forum Infectious Diseases|October 24, 2018
Safety of Delafloxacin: Focus on Adverse Events of Special InterestThomas Lodise, Ralph Corey, David Hooper, et al.
Pageof 4